Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Hematologic Neoplasms Clinical Trials

A listing of Hematologic Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (156) clinical trials

CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.

Viral infections remain an important cause of morbidity and mortality after allogeneic stem cell transplantation (SCT), especially after myelo-ablative conditioning and if the donor is antigen-mismatched or haplo-identical.. In the described setting the patient's own immune system has been destroyed by the necessary highly immuno- and myelo-ablative conditioning and all ...

Phase

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

This is a phase I, dose-escalation study followed by a phase II study.

Phase

Cologne Cohort of Neutropenic Patients (CoCoNut)

This prospective cohort was established with the aim of a comprehensive data collection of all patients developing neutropenia after receiving chemotherapy for any kind of malignant disease, treated in the University Hospital of Cologne.

Phase N/A

Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing HSCT

Hematopoietic stem cell transplant candidates are randomized to vitamin D supplementation or usual care. Five milligrams (200,000 IU) of cholecalciferol is injected to intervention group before stem cell transplantation. Additional supplementation of cholecalciferol during follow-up period is determined according to the level of 25(OH)D3. The primary outcome is the incidence ...

Phase

Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients

Pneumocystis jiroveci pneumonia (PcP) increased in non HIV immunocompromised patients. Mortality remains high for those patients with comorbidities (50% for patients with the most severe Pneumocystis pneumonia). Physiopathology, characteristics and outcome of PcP in non-HIV patients remains different from those in HIV patients. Steroids in HIV patients with PcP has ...

Phase

Role of CX3CR1-expressing Cells in Hematologic Malignancy

Bone marrow aspirates will be obtained from newly diagnosed MM and DLBCL patients at the time of diagnosis and relapse. Peripheral blood will be obtained at the time of diagnosis, finishing treatment, 3 months after treatment and relapse. The investigators will analyze the cell fractions of CD11b+ CX3CR1+ cells and ...

Phase N/A

Genomic Testing and Resulting Medical Decisions

In the situation of enormous possible beneficial options for patients, health care systems, researchers and companies and the simultaneously present high number of uncertainties, the establishment of an independent registry for patients undergoing any type of comprehensive genomic profiling offers many advantages. In particular, an overview of the speed of ...

Phase N/A

Tissue Blood and Body Fluid Sample Collection From Patients With Hematologic Cancer

OBJECTIVES Provide source of patient tissue, blood, and body fluid samples for ongoing diagnostic, prognostic, or immune-monitoring studies. Support and enhance translational, clinical and basic research for Lineberger Comprehensive Cancer Center (LCCC) members (and non-members who have an LCCC member as sponsor and collaborator) with IRB-approved studies. Maintain responsible and ...

Phase N/A

Molecular Disease Profile of Hematological Malignancies

BACKGROUND Molecular medicine is the branch of knowledge whose purpose is to elucidate the genetic basis of the diseases, to improve the diagnostic definition and prognostic assessment of patients and to contribute to the development of innovative treatments. Genomic information is increasingly being used in the treatment decision making process ...

Phase N/A

Safety and Efficacy Evaluation of IM19 Cells

Assessment of the Safety and Feasibility of Administering T cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell Hematological Malignancies(including B-cell Acute lymphoblastic LeukemiaB-cell Chronic Lymphocytic LeukemiaNon-Hodgkin's lymphoma) and Determine the Best Dosage.

Phase